Better therapeutic strategies may also be inferred from sequential single-cell characterization of CNV changes in CTCs over the course of treatment; MYC amplification occurred along with AR protein expression and AR amplification in a prostate cancer patient progressing through targeted therapy [27]. Here, AR is linked to prostate carcinoma.